MA-EVERBRIDGE
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management and enterprise safety software applications to help keep people safe and businesses running faster, has announced the completion of its acquisition of Unified Messaging Systems ASA ("UMS"). Based in Oslo, Norway, UMS provides a unique countrywide mobile population alerting system globally and is also one of the leading critical communications providers in Europe. By uniting UMS’s proven mobile alerting, crisis management, and notification applications with Everbridge’s market-leading Critical Event Management (CEM) software platform, the acquisition creates an unparalleled set of solutions to help customers assess threats, initiate and manage incidents, and notify stakeholders from a local neighborhood or building to a countrywide level, and across the globe.
UMS’s Population Alerting System (PAS) provides 2-way SMS broadcast capabilities to an entire mobile population. To accomplish this, UMS has the unique ability to message the mobile phones of anyone connected to a carrier’s cell towers. The company also provides Location-Based Alerting technology which enables municipalities to geographically pinpoint where to send notifications within a region. This capability is equally applicable for national and global companies who want to reach local and traveling employees, automating the alert by preferred language. UMS’s PAS systems are deployed in a number of countries, providing countrywide alerting to Sweden, Norway, the Netherlands, the Bahamas, Singapore, Greece, and Cambodia, as well as in the city of Kiev, and some of the largest states in India.
As one of the leading mass notification providers internationally, UMS significantly increases Everbridge’s international reach. UMS supports, for example, over 1,200 customers in Northern Europe and reaches over 500 million people globally via population alerting. Its crisis and emergency management product Previstar is used for planning and resource management purposes by major public safety agencies in such places as Virginia, Georgia, Massachusetts, West Bengal in India, as well as by the U.S. Navy. Previstar will considerably enhance Everbridge’s crisis management capabilities.
“We are thrilled to welcome UMS to the Everbridge family, accelerating our international growth and creating the most comprehensive Critical Event Management platform for business, state and local government, and now entire countries,” said Jaime Ellertson, CEO of Everbridge. “UMS provides Everbridge with a passionate and customer-focused team of experts, differentiated technology, and a shared mission to keep people safe and businesses running during a critical event.”
Together, Everbridge and UMS form a global team of over 700 employees dedicated to delivering innovative, differentiated solutions for critical event management. The collective entity expands Everbridge’s international expertise in business continuity, emergency response, and critical event planning, while providing UMS customers access to Everbridge’s Critical Event Management platform for improved messaging scale and delivery across the world.
“Everbridge’s extensive technical capabilities, the breadth of its offerings, and the experience of its global team made for a natural fit with UMS,” said Espen Gylvik, Chief Executive Officer, UMS. “We look forward to aligning with the market leader to provide critical services and innovative communication solutions to make a significant difference in people’s lives.”
The acquisition values the total share capital of UMS at approximately NOK 268 million, or approximately USD $33.6 million.
About Everbridge
Everbridge,
Inc.
(NASDAQ: EVBG) is a global software company that provides
enterprise software applications that automate and accelerate
organizations’ operational response to critical events in order to keep
people safe and businesses running faster. During public safety threats
such as active shooter situations, terrorist attacks or severe weather
conditions, as well as critical business events such as IT outages,
cyber-attacks or other incidents such as product recalls or supply-chain
interruptions, over 3,700 global customers rely on the company’s
SaaS-based platform to quickly and reliably aggregate and assess threat
data, locate people at risk and responders able to assist, automate the
execution of pre-defined communications processes, and track progress on
executing response plans. The company’s platform sent over 2 billion
messages in 2017 and offers the ability to reach more than 200 countries
and territories with secure delivery to over 100 different communication
devices. The company’s critical communications and enterprise safety
applications include Mass Notification, Incident Management, Safety
Connection™, IT Alerting, Visual Command Center®, Crisis Commander®,
Community Engagement™ and Secure Messaging. Everbridge serves 9 of the
10 largest U.S. cities, 8 of the 10 largest U.S.-based investment banks,
25 of the 25 busiest North American airports, six of the 10 largest
global consulting firms, six of the 10 largest global auto makers, all
four of the largest global accounting firms, four of the 10 largest
U.S.-based health care providers and four of the 10 largest U.S.-based
health insurers. Everbridge is based in Boston and Los Angeles with
additional offices in San Francisco, Lansing, Orlando, Beijing, London,
and Stockholm For more information, visit www.everbridge.com
,
read the company blog
,
and follow on Twitter
and Facebook
.
Cautionary Language Concerning Forward-Looking Statements
This
press release contains “forward-looking statements” within the meaning
of the “safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including but not limited to, statements regarding
the anticipated opportunity and trends for growth in our critical
communications and enterprise safety applications and our overall
business, our market opportunity, our expectations regarding sales of
our products, and our goal to maintain market leadership and extend the
markets in which we compete for customers. These forward-looking
statements are made as of the date of this press release and were based
on current expectations, estimates, forecasts and projections as well as
the beliefs and assumptions of management. Words such as “expect,”
“anticipate,” “should,” “believe,” “target,” “project,” “goals,”
“estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,”
variations of these terms or the negative of these terms and similar
expressions are intended to identify these forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which involve factors or circumstances that are
beyond our control. Our actual results could differ materially from
those stated or implied in forward-looking statements due to a number of
factors, including but not limited to: our ability to successfully
integrate businesses and assets that we may acquire; the ability of our
products and services to perform as intended and meet our customers’
expectations; our ability to attract new customers and retain and
increase sales to existing customers; our ability to increase sales of
our Mass Notification application and/or ability to increase sales of
our other applications; developments in the market for targeted and
contextually relevant critical communications or the associated
regulatory environment; our estimates of market opportunity and
forecasts of market growth may prove to be inaccurate; we have not been
profitable on a consistent basis historically and may not achieve or
maintain profitability in the future; the lengthy and unpredictable
sales cycles for new customers; nature of our business exposes us to
inherent liability risks; our ability to attract, integrate and retain
qualified personnel; our ability to maintain successful relationships
with our channel partners and technology partners; our ability to manage
our growth effectively; our ability to respond to competitive pressures;
potential liability related to privacy and security of personally
identifiable information; our ability to protect our intellectual
property rights, and the other risks detailed in our risk factors
discussed in filings with the U.S. Securities and Exchange Commission
(“SEC”), including but not limited to our Annual Report on Form 10-K for
the year ended December 31, 2016 filed with the SEC on March 23, 2017.
The forward-looking statements included in this press release represent
our views as of the date of this press release. We undertake no
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this
press release.
All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180410005436/en/
Contact:
Media Contact:
Everbridge
Jeff Young, 781-859-4116
jeff.young@everbridge.com
or
Investor
Contact:
ICR
Garo Toomajanian, 818-230-9712
ir@everbridge.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
